质子泵抑制剂对大鼠脊柱融合模型骨形成的影响
研究采用大鼠后外侧脊柱融合模型,将38只雌性大鼠分为生理盐水对照组和泮托拉唑组,每日腹腔注射给药,术后8周通过手法触诊、microCT、组织学分析和生物力学测试评估融合情况。结果显示两组融合率无显著差异(100% vs 94%),泮托拉唑组平均融合评分显著降低,但新骨形成体积和生物力学强度、刚度无显著差异。作者认为质子泵抑制剂不抑制融合率、骨形成或生物力学完整性,但较低的融合评分提示可能仍存在负面影响。
要点
- 大鼠后外侧脊柱融合模型中,对照组与泮托拉唑组融合率无显著差异(100% vs 94%)。
- 泮托拉唑组平均融合评分显著低于对照组,但microCT新骨体积和生物力学测试无显著差异。
- 作者认为质子泵抑制剂不抑制融合率、骨形成或生物力学完整性,但较低融合评分提示可能仍有负面影响。
核心结论
- 本研究表明给予质子泵抑制剂不抑制融合率、骨形成或影响融合的生物力学完整性。
- 泮托拉唑组较低的融合评分提示可能仍存在负面影响。
- 未来研究将探索融合块中的生长因子和蛋白表达,并使用更高剂量质子泵抑制剂以充分辨别其对脊柱融合的影响。
研究设计与样本
- 大鼠后外侧脊柱融合模型。
- 38只雌性大鼠接受后外侧腰椎脊柱融合,分为生理盐水对照组和泮托拉唑组,泮托拉唑通过每日腹腔注射给药。
- 术后8周使用手法触诊、microCT、组织学分析和生物力学测试评估脊柱。
主要发现
- 对照组与质子泵抑制剂组融合率无显著差异(100% vs 94%)。
- 泮托拉唑组平均融合评分显著低于对照组。
- microCT显示双侧融合标本中新骨形成的平均体积在质子泵抑制剂组较低,但差异无统计学显著性。
- 生物力学测试显示两组融合块的强度和刚度无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来研究将探索融合块中的生长因子和蛋白表达,并使用更高剂量质子泵抑制剂以充分辨别其对脊柱融合的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Rat posterolateral arthrodesis model. OBJECTIVE: Quantify the impact of administration of a proton pump inhibitor on spine fusion. SUMMARY OF BACKGROUND DATA: Proton pump inhibitors (PPIs) are widely used for gastrointestinal disorders and for ulcer prophylaxis in patients taking non-steroidal anti-inflammatory drugs. PPIs cause chronic acid suppression which has been found to result in decreased bone mineral density, increased fracture risk, and impaired fracture healing. Despite advances in surgical techniques, pseudarthrosis still occurs in up to 24% of patients requiring revision surgery following spinal fusion procedures. Thus, there are likely many unidentified risk factors. While PPIs have been hypothesized to impact fracture healing, no study has evaluated their effect on spine arthrodesis rates. METHODS: Thirty-eight female rats underwent posterolateral lumbar spinal fusion. Rats were divided into two groups: normal saline control and pantroprazole, which was administered by daily intraperitoneal injections. At 8 weeks postoperative spines were evaluated with manual palpation, microCT, histologic analysis, and biomechanical testing. RESULTS: Fusion rates of the control group and PPI group were not significantly different (100% vs. 94%). Average fusion scores were significantly lower in the pantoprazole group. New bone formation identified on microCT imaging of bilaterally fused specimens demonstrated a lower average volume of newly generated bone in the PPI group, but this difference was not significant. Biomechanical testing demonstrated no significant difference in strength or stiffness of the fusion mass between the groups. CONCLUSION: This study demonstrates that administration of PPIs does not inhibit fusion rates, bone formation, or affect biomechanical integrity of fusion. However, lower fusion scores in the PPI group suggest that a negative impact may still exist. Future studies will explore growth factor and protein expression in the fusion masses as well as utilize higher doses of PPI to fully discern their effect on spine fusion. LEVEL OF EVIDENCE: N/A.
引用
- Sonn KA, Wallace SJ, Yuan FNF, et al. The Effect of Proton Pump Inhibitors on Bone Formation in a Rat Spinal Arthrodesis Model. Spine (Phila Pa 1976). 2019. PMID: 30664099. doi:10.1097/BRS.0000000000002987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。